671 Checkpoint inhibitors and targeted therapy combination (triple therapy) in treating metastatic melanoma: a systematic review and meta-analysis
Year: 2026
Type: conference-abstract
Abstract: Background Immune checkpoint inhibitors (ICIs) have demonstrated durable survival benefits; targeted therapy provides rapid disease control in patients with Metastatic melanoma. However, there are high resistance rates when used alone. Triple therapy combining ICIs with targeted therapy has emerged, but with limited evidence. We aim to investigate the effectiveness and safety of triple approach in treating Metastatic Melanoma.Methods A thorough literature search was conducted across PubMed, Scopus and Web of Science up to 20/Feb/2025. Eligible studies included RCTs, non-randomized trials, and cohorts comparing triple consisting of two targeted therapies and one ICI versus dual targeted therapy and placebo in adults with Metastatic Melanoma. R was used to conduct statistical analysis. PROSPERO registration number: CRD420250655934Results 10 studies including 8 RCTs with 1465 and 1475 patients in triple and dual therapy receptively were included. Significant difference were observed in Progression-Free Survival (PFS) with summary HR (SHR) of 0.69 (95%CI, [0.57–0.84]) ( figure 1) and Overall Survival (OS) with SHR of 0.79 (95%CI, [0.67–0.93]) (figure 2), with being Pembrolizumab, Dabrafenib and Trametinib regimen showing more promising effect in both PFS (SHR: 0.51 vs. 0.79 vs. 0.82) and OS (SHR: 0.62 vs. 0.84). While no significant difference was observed in Objective Response Rate (ORR) with an Odds Ratio of 1.06 (95% CI [0.87–1.29]). Discontinuation of all drugs didn’t reach significant level with 0.7% (95% CI: -2.7% to 3.9%) higher cessation rate in triple therapy group, while discontinuation any drug revealed a highly significant result (p < 0.00001), with 12.8% (95% CI: 8.1% to 17.5%) higher discontinuation in patients receiving the triple therapy. Pyrexia was the most frequently reported adverse event with mostly happen in the triple therapy group.Conclusions Triple therapy improves PFS and OS compared to dual therapy in patients with advanced melanoma but is associated with increased drug discontinuation rates, toxicities and higher cost. Further regimens, especially Pembrolizumab, Dabrafenib and Trametinib, should be navigated more extensively for long-term treatment effect and adverse events.Abstract 671 Figure 1Progression-free survival hazard ratio forest plotAbstract 671 Figure 2Overall survival hazard ratio forest plot
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Keywords: metastatic melanoma, immune checkpoint inhibitors, targeted therapy, triple therapy, pembrolizumab, dabrafenib, trametinib, progression-free survival, overall survival, treatment discontinuation, fever, adverse events, combination therapy, drug resistance, PD-1 inhibitors, MAPK inhibitors, immune-related adverse events
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225292425
